These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30142012)

  • 21. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner.
    Jepsen SL; Albrechtsen NJW; Windeløv JA; Galsgaard KD; Hunt JE; Farb TB; Kissow H; Pedersen J; Deacon CF; Martin RE; Holst JJ
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets.
    Liu L; Omar B; Marchetti P; Ahrén B
    Biochem Biophys Res Commun; 2014 Oct; 453(3):398-404. PubMed ID: 25268763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
    Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
    Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.
    Plamboeck A; Holst JJ; Carr RD; Deacon CF
    Diabetologia; 2005 Sep; 48(9):1882-90. PubMed ID: 16025254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
    Nonogaki K; Kaji T
    Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
    Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
    Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
    Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
    J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
    Duez H; Smith AC; Xiao C; Giacca A; Szeto L; Drucker DJ; Lewis GF
    Endocrinology; 2009 Jan; 150(1):56-62. PubMed ID: 18801896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 Receptor Blockade Reduces Stimulated Insulin Secretion in Fasted Subjects With Low Circulating GLP-1.
    Gray SM; Hoselton AL; Krishna R; Slentz CA; D'Alessio DA
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2500-2510. PubMed ID: 35775723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
    Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
    Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.